NKMAX Co., Ltd.

1 clinical trials · Sponsor

Record	Firm	Date
A Study to Evaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor Treatment (NCT04872634)	NKMAX Co., Ltd.	2021-07-08

Every clearance here is in the API, with alerts when new ones post.